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Abstract
Background: Although among women a decreasing prevalence of human papillomavirus (HPV) infection with
increasing age has been consistently observed in high-resource countries, different age profiles have been reported
elsewhere.
Methods: We compared the age profile of high-risk (HR)-HPV prevalence in nine different areas of Northern and
Central Italy by studying the women recruited in the intervention arm of the New Technologies in Cervical Cancer
study and tested by Hybrid Capture 2. Differences in the age-distribution of HPV infection were investigated in
each centre by the joinpoint approach in a logistic model. 46,900 women aged 25 to 60 years were included in
the analysis.
Results: The HR-HPV age-standardised (on Italian population) prevalence ranged from 5.7% (Trento) to 10.3%
(Ravenna). HR-HPV prevalence decreased as a logistic function of increasing age in 6 of 9 centres (Trento, Verona,
Florence, Bologna, Imola, and Viterbo). The effect of age on HR-HPV prevalence slopes did not differ significantly
among these 6 centres, whereas significant heterogeneity in intercepts (p < 0.001) was found, reflecting different
overall HR-HPV prevalence between centres. One significant joinpoint was observed in 2 centres (Padua and
Ravenna), indicating that the decrease in HR-HPV prevalence by age was better described using a function
composed with two logistic segments. In Padua HR-HPV prevalence decreased only slightly up to 39 years but
showed a steep downturn thereafter. In Ravenna HR-HPV prevalence decreased steeply down to 45 years of age
and then showed a plateau. Finally, in Turin two significant joinpoints were observed: prevalence decreased only
after age 29 and showed a plateau after age 39.
Conclusions: Our results showed substantial differences in overall and age-specific HR-HPV prevalence across
Italian areas. These findings may be related to different timing of changes in sexual behaviours across regions.
Age-specific HR-HPV prevalence in Italy does not support an influence of age per se.
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Background
The prevalence of cervical human papillomavirus (HPV)
infection varies across populations and according to a
woman’s age. Studies from Europe [1-4] and North
America [5-7] showed high HPV prevalence in young
women with subsequent marked declines after age 25 or
so. This pattern was also observed in industrialized
countries in South America and Asia, e.g., Argentina [8]
and Korea [9]. Some studies in Central [10,11] and
South America [12-14] showed a more modest second
peak in HPV prevalence in women 45 or 55 years or
older. In addition, a few studies found that in some
low-resource populations HPV prevalence remains high
at any age [15-19].
The very steep increase in the cumulative incidence
of HPV infection observed among women who had
recently become sexually active suggested that a majority
of women acquire the infection in the first few years after
sexual debut [6,20]. However, clear evidence emerged
from cohort studies suggesting that middle-aged women
do not only harbour long-term HPV persistent infections
but also new incident infections [21,22]. The geographic
heterogeneity in age-specific HR-HPV prevalence in dif-
ferent populations suggests that population-specific fac-
tors, including sexual behaviour at different ages and birth
cohort, need to be taken into account along with the
natural history to characterize the HR-HPV infection
epidemiology [23].
Previous studies were, however, based on samples of a
few hundreds or few thousands women overall, limiting
the possibility of studying age effect in detail. Therefore,
we aimed at assessing HR-HPV prevalence and possible
variations in the age-distribution of HPV prevalence in
46,900 women from a large multicentre randomised con-
trolled trial conducted across nine different areas in Italy.
Methods
The New Technologies in Cervical Cancer (NTCC) study
is a randomized trial of screening methods (conventional
cytology versus HPV testing) for which the main endpoint
was histologic detection of cervical intraepithelial neopla-
sia of grade 2 or more. Our report is based only on the
HPV testing arm of NTCC. NTCC was conducted within
organised cervical cancer screening programmes in nine
centres in Northern and Central Italy (Turin, Trento,
Padua, Verona, Florence, Bologna, Imola, Ravenna and
Viterbo) and was considered in determining HPV preva-
lence. Figure 1 shows the location of participating centres
within Italy. Turin is a large industrial city of about 1
million inhabitants. Padua, Bologna and Florence are
middle-sized towns of about 2–300,000 inhabitants. The
Verona screening programme targeted a mainly rural area
close to the town of Verona. The remaining screening
programmes included the populations of small towns
(50–100,000 inhabitants) and surrounding rural areas. In
particular, the Trento screening programme served a
mountain area while Ravenna is close to an important
touristic resort area on the Adriatic Sea.
Methods of recruitment and randomisation of NTCC
study have been previously described [24-26]. Briefly,
following an invitation sent to the entire target population,
women aged 25–60 years attending a new round of
cervical screening were assigned randomly to either
conventional cytology or HPV testing arm. Women who
were pregnant, reported to be virgin, had undergone hys-
terectomy, or had been treated for cervical intraepithelial
neoplasia (CIN) or cancer in the past 5 years were ex-
cluded. Seventy-four percent of eligible women consented
to the study and were randomized [27]. All participants
provided written informed consent. The study was ap-
proved by the ethics committee of the coordinating
centre in Turin (Commissione sperimentazioni cliniche
della Regione Piemonte - Comitato etico di riferimento
regionale, art.7, DM 18 marzo 1998) and by local ethics
committees of each participating centre. Baseline cha-
racteristics of NTCC participants have been previously
described [24-27].
In the HPV testing arm, exfoliated cervical cells were
collected using a plastic Ayre’s spatula and a cytobrush,
and eluted into the PreservCyt buffer (NTCC phase 1)
or in the standard transport medium (Qiagen Incorpo-
rated) (NTCC phase 2). The Hybrid Capture 2 (HC2)
hybridization assay (Qiagen, Hilden, Germany) targeting
HR-HPV types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58,
59 and 68, was used to determine HR-HPV presence
with a cut point of 1 relative light unit (RLU) for HPV
positivity, as recommended by the manufacturer. High
reproducibility of HPV testing between laboratories was
documented [28].
HR-HPV status from the first valid HC2 test was con-
sidered. For each centre, HR-HPV prevalence was stan-
dardized to the 2004 Italian female population in the
same age groups for year 2004 aged 25–60 years [29].
The heterogeneity in age-standardized HPV prevalence
across centres was assessed using the inverse-variance
method and tested with the Q statistics from the ran-
dom effects pooling method proposed by DerSimonian
and Laird [30].
The age-distribution of HR-HPV prevalence in each
recruitment centre was assessed performing a logistic
joinpoint regression analysis. This method allows cha-
racterizing the age-specific prevalence using joint linear
segments with different slopes, where the joinpoints
represent the points of change in slope. If no significant
joinpoints were identified, we characterized the age-
specific HR-HPV prevalence profiles using a standard
logistic regression with studied differences between
centres and logistic effect of age as suggested by the
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intercepts and the slopes. For the centres without any
significant joinpoint we tested the significance (signi-
ficance level < 0.05) of differences between centres in
intercepts, reflecting different overall HR-HPV preva-
lence, and age slopes, reflecting different declines of
HR-HPV prevalence as a function of age. To test for
significant differences in intercepts between centres we
performed a log-likelihood ratio test comparing two
logistic regression models: one accounting only for age
as independent variable, the other for both age and cen-
tres. Similarly, to test for different declines of HR-HPV
prevalence as a function of age among centres, we tested
the statistical significance of the interaction between
centres and age performing a log-likelihood ratio test.
To test for the presence of statistically significant (sig-
nificance level < 0.05) joinpoints and to estimate their
value, we used the package “ljr” from the CRAN reposi-
tory [31]. In particular, the used function tests, based on
the likelihood ratio test statistic, the null hypothesis of j
joinpoint(s) versus the alternative of j + 1 joinpoint(s).
The p-value is determined by a Monte Carlo method
[32]. We allowed for up to three possible joinpoints
(jmax = 3) and set as significance level < 0.05). All the
other statistical analyses were performed using STATA
software (StataCorp. 2011. Stata Statistical Software: Re-
lease 12. College Station, TX: StataCorp LP).
Results
A total of 47,369 women were randomly assigned to the
HPV testing arm. After the exclusion of 469 women
who did not have any valid HPV test, 46,900 women
could be included in the present analysis.
Table 1 shows the number of women found to be
positive for HR-HPV types by centre and age group.
The overall HR-HPV unadjusted prevalence was 8.4%;
the overall age-specific prevalence steadily decreased as
a function of age, from 15.1% at age 24–29 to 4.0% at
age 55–60. Additional file 1: Figure S1 section, shows
the HR-HPV prevalence (%) as a function of age for
each recruitment centre. Age-standardized prevalence
varied significantly, as assessed using the inverse-variance
method and tested with the Q statistics (p-value <0.001),
by centre with the lowest values in Trento (5.7%; 95% con-
fidence interval (CI): 4.9-6.5) and Viterbo (7.4%; 95% CI:
6.4-8.4) and the highest value in Ravenna (10.3%; 95% CI:
9.0-11.6) (Figure 2). All the remaining centres had values
between 8.2% and 9.4%.
Figure 1 Location of new technologies in cervical cancer study recruitment centres within Italy.
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No significant joinpoints were observed in six of the
nine centres (Verona, Trento, Bologna, Imola, Florence
and Viterbo). HR-HPV prevalence in these centres de-
creased as a logistic function of increasing age. Significant
heterogeneity in intercepts (p < 0.001), as assessed
performing a log-likelihood ratio test, was found between
centres, reflecting different overall HR-HPV prevalence
(Figure 3). While HR-HPV prevalence showed a steeper
decline with age in Bologna, Florence and Imola than in
Trento, Verona and Viterbo, the test for heterogeneity of
age slopes did not reach statistical significance (p = 0.08).
Figure 4 shows age-specific prevalence and the join-
points regression for the three centres where at least
one statistically significant (p < 0.05) joinpoint was
found. In Turin two significant joinpoints were ob-
served: HR-HPV prevalence remained high up to age
30 years, decreased steeply between age 30 and 38 and
maintained a very slow decline after age 38. In Ravenna
HR-HPV prevalence decreased until 45 years of age and
reached a plateau thereafter, with a slightly higher
prevalence observed in the oldest women. In Padua,
HR-HPV prevalence showed a very slow decline between
Table 1 Prevalence of hybrid capture 2 positive-women by age and recruitment centre
HPV+/Tested women (prevalence%)

































































































































































Figure 2 The age-standardised prevalence, by recruitment centre. CI: confidence interval; HR: high-risk; HPV: human papillomavirus.
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age 25 and 39, with a higher prevalence for women aged 35–
39 than in any other centre (14.1% vs. 9.5% on average), and
subsequently had a steep downturn with the lowest preva-
lence observed in the oldest age groups.
Discussion
We observed geographical variation in age-standardized
and age-specific prevalence of HR- HPV infection in the
Italian centres participating in the NTCC study; with
the highest age-standardized prevalence in Ravenna
(close to a touristic sea resort area) almost twice that of
Trento (a mainly rural mountain area), the lowest
prevalence. Given that relevant differences in biological
features of HR-HPV infections across Italian regions are
implausible, the observed geographical variations are
likely to reflect differences in sexual behaviour across
Italian areas.
In addition, although in all study centres HR-HPV
prevalence followed the general pattern of decrease with
increasing age typical of industrialised countries, qualita-
tive differences were found (Ravenna, Turin and Padua)
in the shape of age specific prevalence. In the majority
of NTCC centres HR-HPV prevalence decreased as a
logistic function of increasing age, i.e., a logistic function
described HR-HPV prevalence reduction within the
considered 25-to-60-year-old age range. In Turin and
Padua, however, women showed higher HR-HPV infec-
tion prevalence up to about age 30 and 40 years, respect-
ively. The same age-distribution of HR-HPV prevalence
in Turin had been found in a previous smaller study [4].
Consistent high prevalence of HR-HPV infection in
25-to-30 and 25-to-39-year-old women in Turin and
Padua, respectively, the two largest Northern Italian
towns included in the NTCC study, could reflect the
increasing delay in age at first marriage [33]. In turn, this
may result in more sexual promiscuity before marriage,
and thus increased HPV exposures. Also, high pre-
valence of HR-HPV infection in Turin and Padua could
derive from birth cohort effects mainly due to sexual
behavioural changes in younger birth cohorts, leading to
earlier initiation of sexual activity compared to elsewhere
in Italy. A similar delay in the decline in HR-HPV preva-
lence was reported in Poland [34]. Ravenna was the centre
that had the highest overall HR-HPV prevalence with a
second peak in prevalence detected above age 45, possibly
reflecting substantial HR-HPV exposures among middle-
aged women or their partners in an area where tourism
has been flourishing for at least five decades.
Of notice, a steeper decrease in HR-HPV prevalence
with age than that found in the NTCC study was ob-
served in a study conducted in Central and Southern
Italy [35]. This finding suggests that age-specific sexual
patterns across Italy differ, with a more pronounced re-
duction of sexual activity or promiscuity with aging in
Southern Italy. Geographical differences in sexually re-
lated behaviours across Italy have also been reported
from a nation-wide survey on sexual activities [36] and
contraceptive use [37]. Unfortunately, surveys of sexual
behaviour in Italy are sparse and do not allow clear com-
parisons between birth cohorts.
Differences in sexual habits and birth cohort effects
may herald different future changes in the incidence
of precancerous and cancerous lesions of the cervix
in different parts of Italy. Increases in both incidence
[38] of and mortality [39] from cervical cancer in youn-
ger cohorts have been observed in many European
Figure 3 Model-based age-specific prevalence for centres without significant joinpoint (i.e. (Verona, Trento, Bologna, Imola, Florence
and Viterbo). The thick solid curve shows the age-specific prevalence pooled across recruitment centres.
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countries and in others, like England, were plausibly
masked by screening efficiency [40].
The variation in the shape of age-specific HR-HPV
prevalence observed between centres in the NTCC study
could also derive from different population mixing. On
account of important migratory waves, for instance, less
than half of the population living in Turin in 2011 was












































































Figure 4 Age-specific prevalence and the fitted regression according to the joinpoint logistic regression analysis for centres with
significant joinpoint (i.e. Turin –Panel A, Ravenna – Panel B, and Padua – Panel C). HC2: Hybrid Capture 2.
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industrialized countries, Turin is constantly subject to
rural-to-urban migrations. Main reasons for immigration
from both other Italian areas and abroad are studying
and working purposes. We speculate that the constant
inflow of relatively young immigrants may have an
impact on sexual promiscuity and transmission chain of
HPV infections. The consequences of immigration on
older birth-cohorts are of less straightforward interpre-
tation. Demographically relevant migrations to Turin,
initially from Southern and North-eastern Italy, started
in the 1960s. Almost half the women migrated to Turin
from Southern Italy arrived during such period and
would have not fallen in the age range eligible for the
NTCC study [41].
Our study has strengths and weaknesses. Study popu-
lation is large and can be considered well representative
of women aged between 25 and 60 years who participate
in screening in the study areas. In a previous study of
the determinants of screening attendance in Turin [42],
we found no significant effect of age, education, marital
status or place of birth on response to invitation to
screening. Given the standardization and quality control
assurance of organized screening programmes across
Italy, any selection bias is unlikely to have applied differ-
ently to different study centres or age groups thus
reassuring on the validity of the present comparisons.
The use of a well-validated HPV testing method is
another asset of the present study. A few weaknesses
should also be mentioned. Despite the large size of the
present study, the power to detect significant joinpoints
in age-specific HR-HPV prevalence was limited in the
smaller centres. Lack of inclusion of certain geographic
areas, in particular from southern Italy, makes our
current estimate of HR-HPV prevalence not equivalent
to a national average. Another weakness is lack of indi-
vidual information on place of birth, marital history,
and sexual habits that could have helped elucidating
some of the determinants of variations in HR-HPV
prevalence.
Conclusions
In conclusion, we observed substantial differences in
overall and age-specific HPV prevalence across Italian
areas. These findings may be related to differences in
sexual behaviour of women in different age groups and
birth cohorts and in population mixing across study
areas. Awareness of the existence of age or cohort ef-
fects may be useful in predicting trends in precancerous
and cancerous lesions of the cervix and modelling the
future impact of screening or HR-HPV vaccination in
different Italian areas. In any case, the heterogeneity we
observed does not support an influence of age per se in
HR-HPV prevalence.
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